scholarly journals Wiskott–Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection

2018 ◽  
Vol 6 ◽  
pp. 2050313X1775378 ◽  
Author(s):  
Ryota Kaneko ◽  
Shohei Yamamoto ◽  
Naoko Okamoto ◽  
Kosuke Akiyama ◽  
Ryosuke Matsuno ◽  
...  

Wiskott–Aldrich syndrome is a rare X-linked recessive disease resulting from variations in the WAS gene. Wiskott–Aldrich syndrome is sometimes difficult to differentiate from immune thrombocytopenic purpura. A 2-month-old boy was admitted to our hospital for purpura and thrombocytopenia. His mean platelet volume was reported to be normal. Treatment with intravenous immunoglobulins failed to improve the patient’s platelet count. Subsequently, an acute cytomegalovirus infection was confirmed by serological testing and antigenemia. The patient was diagnosed with immune thrombocytopenic purpura secondary to a cytomegalovirus infection. However, based on the patient’s clinical course and the refractoriness of his condition, Wiskott–Aldrich syndrome was strongly suspected. Through direct sequencing of the genomic DNA of the Wiskott–Aldrich syndrome protein (WASP) gene, we identified a novel missense mutation in exon 3 of the patient’s WASP gene (c. 343 C>T, p. H115T), and the patient was diagnosed with Wiskott–Aldrich syndrome at 3 months after onset. Children with Wiskott–Aldrich syndrome are often initially diagnosed with immune thrombocytopenic purpura, which can lead to inappropriate treatment and delays to life-saving definitive therapy. Our findings imply that Wiskott–Aldrich syndrome should be considered as a differential diagnosis in cases of refractory immune thrombocytopenic purpura combined with a cytomegalovirus infection.

2015 ◽  
Vol 2 ◽  
Author(s):  
Bessy S. Flores-Chang ◽  
Carlos E. Arias-Morales ◽  
Francis G. Wadskier ◽  
Sorab Gupta ◽  
Nicoleta Stoicea

Author(s):  
Sabine Revuz ◽  
Nathalie Vernier ◽  
Leilah Saadi ◽  
Julien Campagne ◽  
Sophie Poussing ◽  
...  

We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse.


2018 ◽  
Vol 69 (11) ◽  
pp. 3285-3287
Author(s):  
Oana Viola Badulescu ◽  
Magda Badescu ◽  
Manuela Ciocoiu ◽  
Madalina Mocanu

Immune thrombocytopenic purpura is a pathological condition in which the decrease in the number of circulating platelets outlines a polymorphic picture. It takes the form of a haemorrhagic syndrome at the facial and mucosal level, manifesting usually through epistaxis, gingivorrhagia, bruising, petechial purpura. Mechanisms of disease onset and symptomatology are not fully known, yet many studies concluded that infectious factors and immunological disorders are involved in the etiopathogenesis of immune thrombocytopenic purpura. Infectious diseases with a possible etiological role in triggering a secondary thrombocytopenic syndrome are predominantly viral: hepatitis virus (B, C) infection, HIV infection, infectious mononucleosis or Cytomegalovirus infection. This paper aims to highlight the involvement of Cytomegalovirus infection in the occurrence of antithrombotic antibodies and haemorrhagic manifestations of immune thrombocytopenic purpura. Determination of the anti-Cytomegalovirus viral serology was performed using the immunochemical method of electrochemiluminescence detection (ECLIA).


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1077-1077
Author(s):  
Eri Tanaka ◽  
Shuji Hayashi ◽  
Katsumichi Fujimaki ◽  
Hiroyuki Fujita

Abstract Refractory Immune Thrombocytopenic Purpura (ITP) is a difficult disease to treat effectively and the mortality approaches nearly 10% over 10 years. Moreover, the side effect profile of chronic steroid administration is undesirable due to the multi-systemic actions of these drugs. Recently, it has been reported in the literature that Rituximab is effective treatment for chronic ITP and it has been used at a dose of 375mg/m2 weekly for up to four weeks, as with lymphoma therapy. Rituximab is an expensive treatment, but according to previous data, patients treated with this drug have responded with increased and sustained platelet counts following only one infusion. Based on this, we treated five refractory ITP patients with single-dose Rituximab and all responded well. Patient 1 is with a 15 year history of ITP and Patient 2 is with a 34 year long history of ITP. Following treatment with Rituximab, although there was an interval of up to 7 months, both eventually responded well. Patient 3 is a 93 year old male who presented to our hospital with an acute presentation of ITP which involved severe gastrointestinal bleeding and this proved to be refractory to both steroids and intravenous immunoglobulins, but responded very quickly to Rituximab within 24 days. Patient 4 is a 75 year old female with diabetes mellitus and three-vessel coronary artery disease who presented with a bleeding diathesis. She was treated with steroids, intravenous immunoglobulins, danazol and azathioprine but with no response. Single-dose Rituximab was effective within 20 days with an improvement in platelet counts. Patient 5 is a 51 year old male with a six year history of ITP who presented to our hospital with massive intraabdominal and gastrointestinal bleeding and after Rituximab therapy his platelet count responded appropriately after 45 days. These patient responses were not associated with prior response to therapy, age, previous splenectomy, duration of ITP or platelet count. All patients tolerated treatment well except one patient who developed SLE-nephrotic syndrome 15 months later although it cannot be proven that such therapy induced this collagen-vascular diseases because Rituximab can be used to actually treat such conditions. Three patients remained in remission for more than one year after just one dose of the Rituximab therapy. Even from our small number of refractory ITP patients treated with Rituximab, it is our experience that single-dose treatment is also effective in some cases of refractory ITP and its effect may continue to provide long-term remission whereby it is now possible to decrease and even stop long-term steroid treatment in such patients.


2018 ◽  
Vol 40 (3) ◽  
pp. 240-242 ◽  
Author(s):  
Maria A. Karalexi ◽  
Marianna Tzanoudaki ◽  
Andreas Fryganas ◽  
Alexia Gkergki ◽  
Dora Spyropoulou ◽  
...  

Lupus ◽  
2021 ◽  
pp. 096120332110651
Author(s):  
Sara Dichtwald ◽  
Avraham Meyer ◽  
Nisim Ifrach

Background Immune thrombocytopenic purpura (ITP) is an autoimmune disease, with accelerated destruction of platelets, estimated to affect 1.6–3.9 in 100,000 adults every year in the European Union. Glucocorticoids and intravenous immunoglobulins are common drug therapies. In refractory cases, drugs that enhance thrombopoiesis may be used. Eltrombopag is a thrombopoietin receptor agonist, known to increase platelet count in patients with refractory ITP. Thrombotic adverse events have been described in association with Eltrombopag administration. Case report A young female patient of Ethiopian ancestry with systemic lupus erythematosus, triple Antiphospholipid (APLA) positive serology and refractory ITP who received Eltrombopag and 2 weeks later developed catastrophic APLA syndrome with severe Libman-Sacks endocarditis of the mitral and aortic valves, multiple intracerebral infracts and arterial thrombosis of the left upper limb. Conclusion Eltrombopag is a salvage drug, used in refractory ITP. Thrombotic adverse events, some of which may be life-threatening, are a possible complication, especially in high-risk patients.


Sign in / Sign up

Export Citation Format

Share Document